Should Eli Lilly Investors Worry About This Unexpected FDA Move?
Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven major gains in recent times. And that's the company's weight loss drugs.
Eli Lilly’s Zepbound to undergo first-of-its-kind study on economic impact
Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...
Can weight-loss drug help employment? This is how obesity drug Zepbound maker Eli Lilly can help UK
In a bid to combat obesity and unemployment, the UK govt is collaborating with Eli Lilly, which will invest £279 mn in a ...
Everyday Health12h
Are Compounded Weight Loss Drugs on Their Way Out?
The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...
Mounjaro is more effective for weight loss than Ozempic. So how does it work? And why does it cost so much?
A weight-loss drug more effective than Ozempic and Wegovy has recently been approved. Here’s how it works and how it compares ...
scrippsnews on MSN14h
FDA is reconsidering its decision to take tirzepatide off its drug shortage list
Pharmacists can continue making compounded versions of generic tirzepatide, the active ingredient in popular medications ...
HealthDay on MSN13h
FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for Now
Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and ...
Eli Lilly to trial use of weight loss drugs to combat unemployment in U.K.
U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a ...
FDA shakes up weight loss market as Mounjaro shortage ends
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
New Statesman3h
Will the Daily Telegraph’s new buyer threaten its independence?
The logic suggested by the Lilly trial is the opposite, however. It proposes that being overweight is a primary cause of ...
Drugmakers can keep making off-brand weight-loss drugs as FDA backpedals
Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...
Compounding pharmacies can make tirzepatide again
Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...